Photo by Reproductive Health Supplies Coalition on Unsplash
In June of 2022 in the case of Dobbs v. Jackson Women’s Health Organization, the Supreme Court overruled Roe v.Wade on the basis that access to abortion is a state issue. Since that decision, some states have passed laws restricting or banning altogether women’s access to abortion. But the Food and Drug Administration approved the distribution of Mifepristone for medical abortions without an in-person visit as a safe practice. Louisiana filed a lawsuit against the FDA for this action and at the end of April 2026, the Fifth Circuit Court of Appeals ruled in favor of Louisiana, restricting women’s access to the drug in states that have banned abortions. On May 4th, the Supreme Court ordered a halt to stopping access to the drug until May 11th so that both sides could respond and the court could consider the issue more fully. HealthCetera host Diana Mason, PhD, RN, FAAN, discussed the case of Louisiana v. the FDA and the Fifth Circuit Court of Appeal’s ruling with Anna Beernstein, principal federal policy advisor for the Guttmacher Institute, a research and policy organization committed to advancing sexual and reproductive health and rights worldwide. This interview first aired on HealthCetera in the Catskills on WIOX Radio on May 6, 2026.
Podcast: Play in new window | Download (Duration: 24:29 — 39.2MB)
Subscribe: RSS
